Zymeworks Biopharmaceuticals - ZYME Real Price to Acquire Entire Company

Zymeworks Biopharmaceuticals (ZYME) - corporate logo

Zymeworks Inc. (ZYME) optimizes antibody creation through an extensive network of external laboratories, minimizing supply chain disruptions and enhancing profitability. The business relies on stable demand in oncology, monetizing licenses through B2B partnerships. This price action reflects an Enterprise Value of 2060.98. Management is currently updating its strategy, attracting investment to develop advanced next-generation drugs.

ZYME (Zymeworks Inc.) Total Company Value history from 11/23/2025 to 10/28/2026

Zymeworks Inc. - analytical breakdowns and key metrics (ZYME)

- price and consensus price forecast:
Market Price Zymeworks Inc|ZYME - Price Target Chart
- market capitalization data:
Market Valuation Zymeworks|ZYME - Enterprise Value
- book capitalization data:
Net Asset Value per Share Zymeworks|ZYME - Company Book Value|Market-to-Book Ratio zymeworks.com|ZYME - Aggregate Company Assets
- debt and liquidity data:
Debt to Equity Ratio Zymeworks Inc.|ZYME - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio zymeworks.com|ZYME - Company Debts|Debts to Book Value Zymeworks
Fundamental valuation:Zymeworks Inc (ZYME)
Original product of Zymeworks

Zymeworks Inc. specializes in developing innovative antibodies to combat oncological diseases within the B2B segment. By analyzing the historical enterprise value trend, an investor can determine the total buyout price of the asset. This metric aggregates market capitalization and debt, minus existing cash reserves. Such a methodology allows for an assessment of the business's real value while accounting for the debt load, which is critical for evaluating capital-intensive biotechnological developments.

Competitors of Zymeworks Inc. (ZYME)

ImmunityBio Inc - Total Enterprise Value|IMCR: Total Company Value|JANX - Real Price to Acquire Entire Company|Enterprise Value RCUS|TNGX (tangotx.com) - Total Enterprise Value|Total Company Value IOVA (Iovance Biotherapeutics, Inc.)|Total Enterprise Value IMTX|Total Company Value Xencor Corp XNCR|Business Value Compass Therapeutics Corp (CMPX)|Replimune Group, Inc. - Enterprise Value|lyell.com - Real Price to Acquire Entire Company|IPHA (Innate Pharma) - Total Company Value|PYXS: Total Enterprise Value|cgen.com (CGEN) - Total Company Value|IOBT (IO Biotech Inc.) - Total Company Value|Total Company Value STRO (Sutro Biopharma, Inc.)|Total Enterprise Value minktherapeutics.com|HOWL: Enterprise Value|Full Takeover Company Value immixbio.com IMMX|ALXO: Real Price to Acquire Entire Company|CUE - Total Enterprise Value|Real Price to Acquire Entire Company PDS Biotechnology Corp (PDSB)|SONN - Value Adjusted for Debt and Cash|MAIA Biotechnology, Inc. - Enterprise Value|LIMN (Liminatus Pharma Inc.) - Company Buyout Price|Total Company Value LVTX|Real Price to Acquire Entire Company NXTC|Total Company Value LPTX (Leap Therapeutics, Inc.)|Real Price to Acquire Entire Company intensitytherapeutics.com INTS|Real Price to Acquire Entire Company SNSE (Sensei Biotherapeutics, Inc.)|Theriva Biologics Inc - Enterprise Value|Gritstone Bio (GRTS) - Total Company Value|KA: Business Value|Total Company Value NEXI|Total Enterprise Value Turnstone Biologics Corp.|Vaccinex - Real Price to Acquire Entire Company|Full Takeover Company Value Harpoon Therapeutics Inc (HARP)